MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected ...

LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported second quarter 2025 financial and ...

Merck pulled off its $10 billion buyout of Verona Pharma last month with little of the wheeling and dealing that typically ...

Investing in index funds is a safe way to grow your portfolio over the years. But there's a huge advantage to picking ...

Verona Pharma plc (NASDAQ:VRNA) is one of the best multibagger stocks according to hedge funds. On July 9, 2025, Merck & Co. unveiled a $10 billion agreement to acquire Verona Pharma at $107 per ...

On July 9, Merck announced that it would acquire Verona Pharma, a U.K.-based biotechnology company specializing in the development of medicines for respiratory diseases. Merck will pay $10 billion in ...

Key Points Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a treatment for COPD -- to its portfolio.

Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a treatment for COPD -- to its portfolio. One of the biggest concerns with ...

It provides Merck with Verona’s newly approved respiratory treatment called Ohtuvayre. Ohtuvayre is designed to treat chronic obstructive pulmonary disease/COPD, commonly known as smoker’s lung.

A rally in big tech stocks led the broader market to a higher close Wednesday, lifting the Nasdaq to an all-time high and helping Wall Street claw back most of its losses from earlier in the week.

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.